INTRODUCTION
============

Inherited metabolic diseases (IMDs) are a heterogeneous group of rare diseases with a collective incidence of 1 in 500 to 4,000 live births, representing a substantial public health burden \[[@B1][@B2][@B3][@B4][@B5]\]. Therefore, a newborn screening (NBS) program was introduced to detect presymptomatic newborns with IMDs. Over the past decade, tandem mass spectrometry (MS/MS) has been a major technological breakthrough for the NBS program by providing a way to detect multiple metabolites simultaneously \[[@B3][@B4][@B5][@B6][@B7]\]. Although the use of MS/MS has enabled cost-effective, rapid IMD identification, there have been some bottlenecks such as false-positives and imprecision \[[@B4][@B5][@B6][@B8]\]. As a second-tier method, enzymatic assays are laborious, time-consuming, and semiquantitative. Sequential Sanger sequencing is hampered by the genetic heterogeneity of IMDs, which results in delayed diagnosis \[[@B8][@B9]\]. These limitations of the current NBS tests have raised a necessity of rapidly diagnosing IMDs by next-generation sequencing (NGS) \[[@B8][@B9][@B10][@B11][@B12]\].

Recent studies have demonstrated that NGS is useful for the molecular diagnosis of some IMDs, including hyperphenylalaninemia, lysosomal storage diseases, and mitochondrial diseases \[[@B13][@B14][@B15]\]. Furthermore, several previous studies revealed the analytical validity and clinical utility of NGS for newborns from the United States \[[@B10][@B12]\]. For example, a NGS panel called NBDx, targeting 126 genes for NBS, was developed, and it demonstrated acceptable analytical performance \[[@B10]\]. Additionally, a previous study revealed that NGS leads to improved outcomes in the neonatal intensive care unit, confirming its clinical utility \[[@B12]\].

Currently, NGS is on the verge of being adopted for NBS. To introduce a multigene panel into an NBS program, some important factors should be considered. First, the analytical validity and clinical utility of NGS should be evaluated in a routine NBS environment as previously noted \[[@B10][@B12]\]. Second, the current biochemical NBS tests cannot be replaced by the exclusive use of NGS. Third, the multigene panel for NBS should be designed with specific considerations of genetic epidemiologic characteristics of the target diseases and population. Until recently, epidemiologic studies of IMDs with NGS in a NBS setting have not been reported.

The epidemiology of IMDs screened by NBS programs varies widely among different ethnic populations \[[@B1]\]. There are considerable differences in the incidence and spectrum of IMDs between Asians and other ethnicities \[[@B1][@B2][@B3][@B4][@B6][@B16][@B17]\]. The collective incidence of IMDs has been reported to be 1 in 2,800 in Korea, 1 in 6,219 in Taiwan, 1 in 6,300 (except hyperphenylalaninemia) in Australia, 1 in 2,000 in Italy, 1 in 4,100 in Germany, and 1 in 500 in a pan-ethnic population \[[@B1][@B2][@B4][@B5][@B18]\].

In addition to ethnic backgrounds, the application of methods like MS/MS have a strong impact on the results of IMD epidemiologic studies. One study reported that there was increase in the incidence of IMDs after the introduction of MS/MS into NBS \[[@B2]\]. Another study revealed that the incidence of medium-chain-acyl-coenzyme A dehydrogenase (MCAD) deficiency was specifically increased after the implementation of MS/MS \[[@B4]\]. Previous genetic epidemiologic studies of IMDs have focused on evaluating a limited number of diseases using conventional molecular methods \[[@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26]\]. Little is known about the incidence and spectrum of IMDs as estimated by the application of NGS as a screening method.

The aim of this study was to develop a multigene panel for detecting IMDs during NBS in Korea, and to evaluate the utility of an integrated screening model based on traditional biochemical tests and a multigene panel in a routine NBS system. In addition, we aimed to investigate genetic epidemiologic characteristics of IMDs in the Korean newborn population using NGS. We determined the overall incidence and mutation spectrum of IMDs based on the integrated screening model and tested for founder effects of recurrent mutations.

METHODS
=======

1. Study participants and study design
--------------------------------------

We developed a multigene panel called NewbornSeq that integrates DNA isolation, targeted sequencing, variant annotation, and data interpretation. We evaluated the sensitivity and specificity of NewbornSeq, using 37 controls (27 positive controls and 10 negative controls). The positive controls were from confirmed IMD patients, as determined by biochemical tests and Sanger sequencing from the Samsung Medical Center, Seoul, Korea. Negative controls consisted of one healthy volunteer sample and nine samples of patients with other diseases which were not screened for in the current NBS program. Between-run reproducibility was measured by detecting mutations in technical duplicates. Turnaround time (TAT) was compared between NewbornSeq and the current NBS tests.

A population study was conducted in 120,700 newborns during routine NBS performed at Green Cross Laboratories in Korea from May 2013 to July 2014. The population in this study represented about 22% of total births (120,700/540,200) in Korea during that period \[[@B18]\]. A total of 269 cases with positive results from current NBS tests were also screened by NewbornSeq. The population samples were applied to an integrated screening model based on biochemical NBS tests and NewbornSeq ([Fig. 1](#F1){ref-type="fig"}). We investigated whether there was any association between abnormal metabolite levels and gene mutations. According to the association results, patients were divided into three groups: (1) the APC group (Association-Positive Cases, with mutations in genes relevant to abnormal metabolite levels), (2) the PCD group (Positive Cases with Discrepancy, with mutations in genes irrelevant to abnormal metabolites), and (3) the PPC group (Presumptive Positive Cases, with metabolite abnormalities only) ([Fig. 1](#F1){ref-type="fig"}). We investigated the mutation incidence and spectrum of the IMDs in the APC group. Researchers were blinded to all information regarding the identification of the newborns and controls. This study was approved by the Institutional Review Board of the Samsung Medical Center; informed consent was exempt because this study was performed by using stored biospecimens.

2. Current newborn screening pipeline
-------------------------------------

Dried blood spots (DBS) were collected from a heel stick on day 3-5 after birth. All NBS tests were performed as a part of the routine NBS program in Korea ([Supplemental Method 1](#S1){ref-type="supplementary-material"}). The cases with metabolite levels higher than the cutoff were retested. \"Presumptive positive\" cases were defined as the individuals with abnormal levels of a metabolite detected from two separate samples.

3. NewbornSeq pipeline
----------------------

### 1) DNA preparation and targeted sequencing

Genomic DNA from 27 positive controls and 269 newborns was extracted from EDTA-anticoagulated whole blood (WB) and DBS, respectively ([Supplemental Method 1](#S1){ref-type="supplementary-material"}). Additional genomic DNA from 10 negative controls was extracted from DBS. Among them, genomic DNA from one healthy control was extracted from WB and DBS to validate the procedure of isolating DNA from DBS. A customized multiplex PCR amplification strategy was applied to analyze the 97 genes in the current Korean NBS panel, by using Ion AmpliSeq Designer software (Life Technologies, Carlsbad, CA, USA; [Supplemental Table S1](#S2){ref-type="supplementary-material"}). All exons and intron sequences of 20 bp around each exon were targeted. The genomic regions with known mutations in the regulatory sequences were included, ultimately resulting in a total of 287 kb for analysis. Ninety-seven percent of targeted bases were covered under this protocol. Targeted sequencing was performed by using the Ion PGM platform (Life Technologies) following the manufacturer\'s instructions ([Supplemental Method 1](#S1){ref-type="supplementary-material"}).

### 2) Bioinformatic analysis, mutation prioritization, and Sanger sequencing

Data were analyzed by using Torrent Suite software (version 4.0.3; Life Technologies). Variant calling was performed by using the \"Germ Line-PGM-High Stringency\" setting ([Supplemental Table S2](#S3){ref-type="supplementary-material"}). The variants were functionally annotated by using the ANNOVAR tool \[[@B27][@B28]\].

To prioritize pathogenic variants, we sequentially applied the following criteria: selection of allele frequency \<0.01 in the 1000 Genome Project (1000GP, <http://browser.1000genomes.org/index.html>), the Exome Sequencing Project (ESP6500, <http://evs.gs.washington.edu/EVS/>), and the Exome Aggregation Consortium (ExAC, <http://exac.broadinstitute.org/>); selection of variants with multiple lines of evidence supporting \"deleterious\" or \"damaging\" effects, using Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping v2 (Polyphen-2), likelihood ratio test (LRT), MutationTaster, MutationAssesor, or FATHMM; selection of variants with a Genomic Evolutionary Rate Profiling (GERP) score higher than 2; removal of common polymorphisms reported in dbSNP v.138; selection of protein-impacting mutations such as nonsense mutations, mutations in GT-AG dinucleotides of the canonical splice sites, and frameshift mutations ([Fig. 2](#F2){ref-type="fig"}). To avoid the false exclusion of pathogenic mutations, we manually reviewed the variants. Finally, the prioritized variants were classified as known pathogenic (KP) mutations and expected pathogenic (EP) mutations. \"Disease-causing mutations\" (DM) in the Human Genome Mutation Database (HGMD) or \"pathogenic\" mutations in ClinVar were categorized as KP mutations, while other variants were considered EP mutations \[[@B29][@B30]\]. Novel EP variants were compared to the reference sequence of whole-exome sequencing data (Korean Reference Genome DB, KRGDB, <http://152.99.75.168/KRGDB/menuPages/firstInfo.jsp>) from 622 healthy Korean individuals. In parallel, we applied the criteria for pathogenicity classification according to the American College of Medical Genetics and Genomics (ACMG) guideline \[[@B31]\], and the prioritized variants were classified as pathogenic variants, likely pathogenic variants, and variants of unknown significance (VUS) ([Fig. 2](#F2){ref-type="fig"}). All prioritized mutations from the APC group and compound heterozygous or homozygous mutations from the PCD group were validated with independent Sanger sequencing ([Supplemental Method 1](#S1){ref-type="supplementary-material"}).

4. Haplotype analysis
---------------------

Haplotype analysis was performed to determine if there were founder effects in recurrent mutations identified from both the APC and PCD groups. The selection criteria of samples and SNPs for genotyping are shown in [Supplemental Method 2](#S1){ref-type="supplementary-material"}. A total of 123 SNPs and seven candidate mutations were genotyped on the Sequenom MassARRAY SNP genotyping platform (Sequenom Inc., San Diego, CA, USA) and by Sanger sequencing, respectively ([Supplemental Table S3](#S4){ref-type="supplementary-material"}). Haplotypes were constructed by using the software PHASE v2.1.1 (<http://stephenslab.uchicago.edu/phase/download.html>). Haplotype frequencies in mutation-positive cases were compared with those of 90 control individuals from the Korean HapMap \[[@B32]\].

5. Statistical analyses
-----------------------

Kruskal-Wallis test was used to compare metabolite levels among APC, PCD, and PPC. The statistical analyses were performed with MedCalc version 11.5.1.0 (Mariakerke, Belgium). *P* values less than 0.05 were considered statistically significant.

RESULTS
=======

1. Performance of the NewbornSeq pipeline
-----------------------------------------

Sequencing quality and coverage statistics using control samples are summarized in [Supplemental Table S4](#S5){ref-type="supplementary-material"}. Taking the median, a total of 99% and 93% of bases were covered by at least 1-fold and 20-fold of coverage, respectively. The median percentage of on-target reads was 93% across the samples. There was no difference between the use of DBS and WB as sample type.

The conventional prioritization method reduced the number of variants per sample from a median of 247 to 4 in the 27 positive control samples (reduction rate of 98%). When the ACMG criteria were applied, the number of variants was reduced to a median of three per sample (reduction rate of 99%). NewbornSeq showed 100% sensitivity and specificity for 97 pathogenic variant alleles (54 causative alleles and 43 incidental alleles) in 27 positive control samples. However, only 96% (93/97) of pathogenic variants were reproducible; four pathogenic variants were not replicated in technical duplicates owing to low coverage less than 20 folds ([Supplemental Table S5](#S6){ref-type="supplementary-material"}). The TAT was a median of 17 days by Sanger sequencing-based second-tier tests, which was reduced to within five days by the application of NewbornSeq ([Supplemental Table S5](#S6){ref-type="supplementary-material"}).

A total of 1,958 variants were called in 269 newborns. We further reduced the number of variants to 244 (0-3 variants/sample) using the conventional criteria. According to the association between the metabolite abnormalities and mutated genes, 59 cases (22%), 125 cases (46%), and 85 cases (32%) were included in the APC, PCD, and PPC groups, respectively ([Fig. 1](#F1){ref-type="fig"}). Sixty-six alleles among 70 mutant alleles from the APC group were confirmed by Sanger sequencing (validation rate of 94%, [Supplemental Table S6](#S7){ref-type="supplementary-material"}).

When comparing metabolite levels among the groups, both thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels among the APC, PCD, and PPC groups were significantly different (*P* values for TSH and FT4 were 0.0044 and 0.0299, respectively; [Supplemental Table S7](#S8){ref-type="supplementary-material"}).

2. Diagnosis of inherited metabolic diseases through the integrated screening model
-----------------------------------------------------------------------------------

In the APC group, 54 cases were validated among 59 cases with mutations in genes relevant to metabolite abnormalities, including congenital hypothyroidism (CH, n=34), galactosemia (n=11), type II citrullinemia (CTLN2, n=3), phenylketonuria (PKU, n=1), methylmalonic aciduria (MMA, n=2), and 3-methylcrotonyl-CoA carboxylase deficiency (3-MCC deficiency, n=3) ([Table 1](#T1){ref-type="table"}). Three cases (IMD_144, IMD_152, and IMD\_ 153) had concurrent heterozygous mutations in different genes within the same metabolic pathway ([Table 2](#T2){ref-type="table"}). The overall positive rate of IMDs was estimated to be 20% (54/269) ([Supplemental Table S8](#S9){ref-type="supplementary-material"}).

We validated 13 cases with biallelic mutations for IMDs in the PCD group. Among them, there were 10 cases with treatable diseases, including ornithine carbamoyltransferase deficiency (OTC deficiency, n=2), type II glutaric aciduria (n=1), lysinuric protein intolerance (n=3), PKU (n=1), CH (n=2), and propionic aciduria (n=1) ([Table 3](#T3){ref-type="table"}). Multiple lines of evidence supporting deleterious effects of the 18 different mutant alleles are summarized in [Supplemental Table S9](#S10){ref-type="supplementary-material"}. Details of the mutations and metabolite abnormalities identified in the PCD group are described in [Supplemental Table S10](#S11){ref-type="supplementary-material"}.

3. Mutation incidence of inherited metabolic diseases
-----------------------------------------------------

We estimated the overall incidence of IMDs based on the current NBS tests to be 1 in 449 in the Korean population. The overall mutation incidence of IMDs calculated through an integrated screening model in the APC group was estimated to be one in 2,235 in the Korean population ([Table 1](#T1){ref-type="table"}). The highest incidences seen for CH and galactosemia were due to *DUOX2* mutations and *GALE* mutations, respectively ([Table 1](#T1){ref-type="table"}).

4. Frequency and spectrum of pathogenic mutations
-------------------------------------------------

A total of 45 different mutations, including 21 known mutations and 24 expected pathogenic variants, were identified in 54 validated APCs ([Table 2](#T2){ref-type="table"}). *In silico* analyses results of validated variants are summarized in [Supplemental Table S11](#S12){ref-type="supplementary-material"}. Recurrent mutations from the APC group were found in CTLN2 \[p.R285 Pfs^\*^2 in *SLC25A13* (n=3)\], CH \[p.R885Q in *DUOX2* (n=3), p.K530X in *DUOX2* (n=2), p.G488R in *DUOX2* (n=2), p.Y138X in *DUOXA2* (n=4), p.R450H in *TSHR* (n=2), p.Y246X in *DUOXA2* (n=2), p.A485D in *TSHR* (n=2), p.A204V in *TSHR* (n=2)\], galactosemia \[p.G302D in *GALE* (n=2), and 3-MCC deficiency \[c.288+2T\>A in *MCCC1* (n=2)\] ([Table 2](#T2){ref-type="table"}).

5. Founder effects
------------------

Seven different recurrent mutations, including *SLC25A13* (p.R285Pfs^\*^2), *DUOXA2* (p.Y138X), *GALE* (p.G302D), *SLC7A7* (p.I166M), *PCCB* (p.Y439C), and *GALT* (p.R224Q) were selected to construct haplotypes. Two samples with *DUOXA2* mutations and three samples with *DUOX2* mutations were added. Haplotype analysis yielded 392.2 kb, 392.6 kb, 775.3 kb, 399.2 kb, and 88.9 kb segments across the following mutations in *DUOXA2*, *DUOX2*, *PCCB*, *SLC25A13*, and *GALT*, respectively. All haplotypes were exclusively observed in mutation-containing cases ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The introduction of NGS is likely to change NBS practices. However, current NBS tests will not be replaced by genomic screening because some diseases, including CH, are not usually genetic conditions despite the fact that some related mutations have been reported. In this study, we noted that TSH levels were higher in PPC group cases than in APC group cases. This indicated the possibility of the presence of true CH in the PPC group. On the other hand, current NBS tests have some shortcomings. Disease risk can be modified by the environment over time, so current biochemical tests could yield false negatives or false positives. To complement the current NBS tests without replacing them, we designed NewbornSeq. NewbornSeq showed superior performance in characteristics important for its application in the NBS program: rapid TAT, small amounts of DNA required, minimally invasive sample type, sensitivity, and specificity.

In this study, we detected IMDs by applying an integrated screening model based on biochemical tests and NewbornSeq. The integrated screening model provided causative mutations in 20% of newborns with positive results from the biochemical tests in a NBS environment. In addition, it is noteworthy that the shortcomings of the current NBS tests, such as overdiagnosis and overtreatment, can be reduced by using the integrated screening model. For instance, galactosemia and a benign variant (known as Duarte galactosemia) cannot be differentiated by using current biochemical NBS tests. Under the current NBS system, a lactose-free diet might be provided to newborns with benign variants. A differential diagnosis between the pathogenic diseases and their benign variants using the integrated screening model could help avoid unnecessary treatment. In this study, we successfully excluded five Duarte galactosemia cases among 43 cases with increased galactose levels, by applying the integrated screening model.

We also identified ten cases with biallelic mutations for preventable IMDs from the PCD group (i.e., secondary findings). These cases would not be detected prior to the implementation of NewbornSeq, suggesting the presence of false negatives in the current NBS pipeline. This might be because some modifiers including prematurity, total parenteral nutrition, or maternal disease may influence the level of metabolites and the age of onset. Although these additional cases were not the primary target of the integrated screening model, they represent an important public health issue. Future studies will determine whether these cases benefited from the early treatment they received.

It should be noted that monoallelic mutations were frequently accompanied by metabolite abnormalities in the APC group. Frequent heterozygote mutations might be attributable to false-negatives in the current NewbornSeq pipeline because: i) missing variants due to low depth of coverage, ii) unidentified mutations in regulatory regions, iii) unidentified mutations in amplification-resistant gene regions, iv) allele dropout due to SNPs in PCR primer-binding sites, or v) structural variations (SV). Actually, we showed the possibility of false-negative results in four pathogenic alleles in control samples due to low depth of coverage. False-negatives can also be attributed to monoallelic mutations described in some of IMDs such as Wilson\'s disease or non-Mendelian mechanisms, such as synergistic heterozygosity \[[@B33][@B34][@B35][@B36]\].

To the best of our knowledge, this is the first genetic IMD epidemiologic study in the NBS setting using NGS. The representativeness of the population in this study prompted us to investigate the genetic epidemiology of IMDs in Korea. The incidence of IMDs based on the integrated screening model was 1 in 2,235 newborns using the APC group ([Table 1](#T1){ref-type="table"}). Using the reported data on the false positive rate (5-10 false positives/1 true positive) of MS/MS, the incidence of IMDs was calculated to be 1 in 2,245 from the biochemical incidence (1:449) \[[@B6]\]. The mutation incidence (1 in 2,235) based on the integrated screening model is quite similar to the disease incidence calculated from the biochemical incidence. This indicates that the integrated screening model provides a reliable and robust estimation of the incidence rate of IMDs, although data regarding clinical phenotypes were not used.

We identified founder effects in p.Y138X in *DUOXA2*, p.R885Q in *DUOX2*, p.Y439C in *PCCB*, and p.R224Q in *GALT*, except the mutation of p.R285Pfs^\*^2 in *SLC25A13*, which was already reported as a founder mutation in Asians \[[@B24]\]. This study suggested that founder mutations could explain most of the recurrent IMD-related mutations in Koreans. Considering the history of the migration of the Mongoloids, further studies are needed to determine the time of origin and distribution pattern of these founder mutations in East Asian populations, including Chinese and Japanese populations.

This study is the first proof-of-concept study for introducing an integrated screening model into the actual NBS system. Importantly, this study raised some issues that should be considered regarding the introduction of NGS in a routine NBS system. First, there is the need for the clinical interpretation of unintended mutations, which would be frequently identified in genetic screening. This study suggested that the long-term follow-up of newborns with secondary findings or monoallelic mutations is necessary. Furthermore, future studies are recommended to determine whether the cases would benefit from the early treatment they received and to investigate whether the pathogenic variants were significantly associated with disease. Second, there is the need for a system that integrates biological knowledge with clinical information. Functional studies on novel mutations are time-consuming and impractical in the NBS setting. In future studies, a more sophisticated system should be introduced to integrate functional data, variant penetrance, and clinical data. Third, there is the need for another analytical platform to detect unidentified mutations, such as SV and regulatory mutations. In this study, although we found one instance of congenital adrenal hyperplasia (CAH) by the use of the integrated screening model, we could not validate the mutations of *CYP21A2*. The absence of CAH might be due to false-positives from the biochemical tests, false-negatives from NewbornSeq, or lack of proper validation methods; it is difficult to detect mutations of the *CYP21A2* gene owing to its high pseudogene homology and frequently observed SV. Future studies are required to develop an additional platform to analyze SVs and genes with pseudogenes for highly suspicious cases.

In summary, we highlighted the epidemiologic and screening implications of NGS through the first population-based study in an NBS environment. This study has led to concerns about the opportunities and challenges for the implementation of NGS in NBS because it detected additional IMD cases that were not detected with the current NBS tests. The integrated screening model will be an effective public health strategy because it will enable faster and more accurate IMD detection. The future use of the integrated screening model as a first-tier approach will likely be more beneficial than the current NBS tests.
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![Workflow for diagnosing inherited metabolic diseases. The study population represented about 22% of births (120,700/540,200) in Korea during the designated period. Using the integrated screening model, results were interpreted and divided into three groups: Association-Positive Cases (Cases with mutations in genes relevant to metabolites), Positive Cases with Discrepancy (Cases with mutations in genes irrelevant to metabolites), and Presumptive Positive Cases (Cases with only metabolite abnormalities). The numbers in brackets indicate the number of samples.\
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![Putative variant prioritization and pathogenicity classification. Pathogenic variants were prioritized based on conventional methods and the American College of Medical Genetics and Genomics criteria in (A) total samples (n=269), (B) association-positive cases (n=125), and (C) in positive cases with discrepancy (n=85). The numbers in brackets indicate the number of different types of variants.\
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###### Mutation incidence and frequency of inherited metabolic diseases detected using an integrated screening model

![](alm-36-561-i001)

  Disease/Gene                                  Mode of inheritance   N of validated cases   Birth prevalence                               
  --------------------------------------------- --------------------- ---------------------- ------------------ ------------- ------------- -------------
  Congenital hypothyroidism                                                                                                                 
   *TSHR*                                       AD/AR                 1                      10                 1in 120,700   1in 12,070    1in 12,070
   *PAX8*                                       AD                    0                      3                  NA            1in 40,233    1in 40,233
   *DUOX2*                                      AD/AR                 2                      12 (14)^\*^        1in 60,350    1in 8,621     1in 8,621
   *DUOXA2*                                     AR                    2                      7 (8)^†^           1in 60,350    1in 15,088    1in 60,350
   *TPO*                                        AR                    0                      1                  NA            1in 120,504   NA
   *SLC5A5*                                     AR                    1                      1                  1in 120,700   1in 120,700   1in 120,700
   Subtotal                                                           6                      34 (37)            1in 20,117    1in 3,550     1in 4,023
  Galactosemia                                                                                                                              
   GALE                                         AR                    1                      6                  1in 120,504   1in 20,084    1in 120,504
   *GALT*                                       AR                    0                      3                  NA            1in 40,168    NA
   *GALK1*                                      AR                    0                      2                  NA            1in 60,252    NA
   Subtotal                                                           1                      11                 1in 120,504   1in 10,955    1in 120,504
  Citrullinemia type II                                                                                                                     
   *SLC25A13*                                   AR                    1                      3                  1in 93,165    1in 31,055    1in 93,165
  Phenylketonuria                                                                                                                           
   *PAH*                                        AR                    0                      1                  NA            1in 93,165    NA
  Methylmalonic aciduria                                                                                                                    
   *MUT*                                        AR                    1                      2                  1in 93,165    1in 46,583    1in 93,165
  3-methylcrotonyl-CoA carboxylase deficiency                                                                                               
   *MCCC1*                                      AR                    0                      3                  NA            1in 31,055    NA
  Total                                         AD/AR                 9                      54 (57)            1in 13,411    1in 2,235     1in 4,828

^\*^One case with concurrent *TSHR* and *DUOX2* mutations; ^†^One case with concurrent *DUOX2* and *DUOXA2* mutations, and the other case with concurrent *DUOXA2* and *PAX8* mutations.

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; NA, not applicable.

###### Diagnosis of inherited metabolic diseases using an integrated screening model

![](alm-36-561-i002)

  Sample ID        Metabolite         cut-off^\*^          NBS tests^\*^   Gene             NT alteration       AA alteration        Conventional criteria   ACMG category   Zygosity   Disease                Frequency in APC
  ---------------- ------------------ -------------------- --------------- ---------------- ------------------- -------------------- ----------------------- --------------- ---------- ---------------------- ------------------
  IMD_26           C3                 5                    10              *MUT*            c.2179C \> T        p.R727X              KP                      P               ComHet     MMA                    1/54
  *MUT*            c.322C \> T        p.R108C              KP              LP                                   MMA                  1/54                                                                      
  IMD_30           C5OH               0.6                  1.102           *MCCC1*          c.475T \> C         p.C159R              KP                      LP              Het        3-MCC deficiency       1/54
  IMD_31           Cit                55                   348             ***SLC25A13***   **c.851delGTAT**    **p.M285Pfs^\*^2**   **KP**                  **P**           **Het**    **CTLN2**              3/54
  IMD_32           Cit                55                   430             ***SLC25A13***   **c.851delGTAT**    **p.M285Pfs^\*^2**   **KP**                  **P**           **Het**    **CTLN2**              3/54
  IMD_39           FT4                0.8                  0.4             *DUOX2*          c.1232G \> A        p.R411K              EP                      VUS             NA         CH                     1/54
  IMD_42           FT4                0.8                  0.6             ***TSHR***       **c.1454C \> A**    **p.A485D**          **EP**                  **VUS**         **NA**     **CH**                 2/54
  IMD_44           TSH                12                   23.3            ***DUOX2***      **c.1588A \> T**    **p.K530X**          **KP**                  **P**           **Het**    **CH**                 2/54
  IMD_47           TSH                12                   13.1            ***DUOX2***      **c.2654G \> A**    **p.R885Q**          **KP**                  **LP**          **Het**    **CH**                 **3/54**
  IMD_48           TSH                12                   25.5            ***DUOXA2***     **c.413dupA**       **p.Y138X**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_50           TSH                12                   34.6            *TSHR*           c.403A \> T         p.N135Y              EP                      VUS             NA         CH                     1/54
  ****TSHR****     **c.1349G \> A**   **p.R450H**          **KP**          **LP**           **Het**             **CH**               **4/54**                                                                  
  IMD_52           TSH                12                   16.5            *PAX8*           c.300dupTACC        p.M102fs             EP                      LP              Het        CH                     1/54
  IMD_54           TSH                12                   13.2            ***TSHR***       **c.611C \> T**     **p.A204V**          **KP**                  **LP**          **Het**    **CH**                 2/54
  IMD_56           TSH                12                   12.1            *DUOXA2*         c.535T \> C         p.Y179H              EP                      VUS             NA         CH                     1/54
  IMD_57           TSH                12                   12.1            *PAX8*           c.192G \> C         p.R64S               EP                      VUS             NA         CH                     1/54
  IMD_66           TSH                12                   21.9            *DUOX2*          c.4010G \> T        p.G1337V             EP                      VUS             Het        CH                     1/54
  ***DUOX2***      **c.1588A \> T**   **p.K530X**          KP              P                Het                 **CH**               2/54                                                                      
  IMD_68           TSH                12                   17              ***DUOX2***      **c.1462G \> A**    **p.G488R**          KP                      LP              Het        **CH**                 4/54
  IMD_79           Gal                13                   21.7            *GALE*           c.1002G \> A        p.W334X              EP                      P               Het        Galactosemia           1/54
  IMD_80           Gal                13                   19              *GALT*           c.50+1G \> A        NA                   KP                      P               Het        Galactosemia           1/54
  IMD_81           Gal                13                   32.2            *GALE*           c.47G \> A          p.S16N               EP                      VUS             NA         Galactosemia           1/54
  IMD_83           Gal                13                   19.8            ***GALE***       **c.905G \> A**     **p.G302D**          **KP**                  **LP**          **Het**    **Galactosemia**       2/54
  IMD_87           Gal                13                   16.5            *GALT*           c.998G \> A         p.R333Q              KP                      LP              Het        Galactosemia           1/54
  IMD_89           Gal                13                   40.4            *GALT*           c.1034C \> A        p.A345D              KP                      LP              Het        Galactosemia           1/54
  IMD_92           TSH                12                   28.5            ***TSHR***       **c.1349G \> A**    **p.R450H**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_100          C5OH               0.6                  2.571           ***MCCC1***      **c.288+2T \> A**   NA                   KP                      **P**           **Het**    **3-MCC deficiency**   2/54
  IMD_101          TSH                12                   14.6            *DUOX2*          c.2635G\>A          p.E879K              KP                      LP              Het        CH                     1/54
  IMD_106          C5OH               0.6                  1.016           ***MCCC1***      **c.288+2T \> A**   NA                   KP                      **P**           **Het**    3-MCC deficiency       2/54
  IMD_112          Gal                13                   17              *GALE*           c.264delT           p.F88fs              EP                      LP              Het        Galactosemia           1/54
  IMD_113          FT4                0.8                  0.3             ***DUOXA2***     **c.413dupA**       **p.Y138X**          KP                      **LP**          **Het**    CH                     4/54
  IMD_124          Gal                13                   17.6            ***GALE***       **c.905G \> A**     **p.G302D**          KP                      **LP**          **Het**    Galactosemia           2/54
  IMD_125          TSH                12                   12.9            ***TSHR***       **c.1349G \> A**    **p.R450H**          KP                      **LP**          **Het**    CH                     4/54
  IMD_139          Gal                13                   27              *GALE*           c.38A \> G          p.Y13C               EP                      VUS             NA         Galactosemia           1/54
  *GALE*           c.10A \> G         p.K4E                EP              VUS              NA                  Galactosemia         1/54                                                                      
  IMD_142          Phe                130                  142.216         *PAH*            c.1065+1G \> A      NA                   KP                      P               Het        PKU                    1/54
  IMD_144          TSH                12                   23.1            ***TSHR***       **c.611C \> T**     **p.A204V**          KP                      **LP**          **Het**    CH                     2/54
  ***DUOX2***      **c.2654G \> A**   **p.R885Q**          KP              **LP**           **Het**             CH                   3/54                                                                      
  IMD_149          TSH                12                   14.2            *DUOX2*          c.3616G \> A        p.A1206T             EP                      VUS             NA         CH                     1/54
  ***DUOX2***      **c.1462G \> A**   **p.G488R**          **KP**          **LP**           **Het**             **CH**               4/54                                                                      
  IMD_152          TSH                12                   12.3            *DUOX2*          c.3329G \> A        p.R1110Q             KP                      LP              Het        CH                     1/54
  ***DUOXA2***     **c.738C \> G**    **p.Y246X**          **KP**          **P**            **Het**             **CH**               3/54                                                                      
  IMD_153          TSH                12                   13.6            ***DUOXA2***     **c.738C \> G**     **p.Y246X**          **KP**                  **P**           **Het**    **CH**                 3/54
  *PAX8*           c.739G \> A        p.E247K              EP              VUS              NA                  CH                   1/54                                                                      
  IMD_159          Cit                55                   128.9           *SLC25A13*       c.1180+1G \> A      NA                   KP                      P               ComHet     CTLN2                  1/54
  ***SLC25A13***   **c.851delGTAT**   **p.M285Pfs^\*^2**   **KP**          **P**                                **CTLN2**            3/54                                                                      
  IMD_164          C3                 5                    9.126           *MUT*            c.1228A \> G        p.I410V              EP                      VUS             NA         MMA                    1/54
  IMD_186          TSH/GAL            12.0/13.0            31.3/13.5       ***DUOXA2***     **c.413dupA**       **p.Y138X**          **KP**                  **LP**          **Hom**    **CH**                 4/54
  IMD_189          TSH/FT4            12.0/0.8             55.7/0.4        ***DUOX2***      **c.1462G \> A**    **p.G488R**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_191          TSH/17α-OHP/FT4    12/12/0.8            54.9/18.1/0.2   *SLC5A5*         c.1060A \> C        p.T354P              KP                      LP              ComHet     CH                     1/54
  *SLC5A5*         c.1605del          p.G535fs             EP              LP                                   CH                   1/54                                                                      
  IMD_196          TSH                12                   94.1            ***DUOX2***      **c.1462G \> A**    **p.G488R**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_197          TSH                12                   14.8            ***TSHR***       **c.1349G \> A**    **p.R450H**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_203          TSH                12                   12.4            *TSHR*           c.1556G \> A        p.R519H              EP                      VUS             NA         CH                     1/54
  IMD_206          TSH                12                   54.8            *DUOXA2*         c.280C \> T         p.R94C               EP                      VUS             NA         CH                     1/54
                                                                           ***DUOXA2***     **c.413dupA**       **p.Y138X**          **KP**                  **LP**          **Het**    **CH**                 4/54
  IMD_209          TSH                12                   15.1            *DUOX2*          c.1319G \> A        p.S440N              EP                      VUS             NA         CH                     1/54
  IMD_210          TSH                0012                 0054.8          *TSHR*           c.1449C \> A        p.N483K              EP                      VUS             NA         CH                     1/54
  IMD_211          TSH                12                   13              *DUOX2*          c.227C \> T         p.P76L               EP                      VUS             NA         CH                     1/54
  IMD_221          TSH                12                   25.7            ***TSHR***       **c.1454C \> A**    **p.A485D**          **EP**                  **VUS**         **NA**     **CH**                 2/54
  IMD_234          Gal                13                   27.7            ***GALK1***      **c.1159G \> A**    **p.A387T**          **EP**                  **VUS**         **NA**     **Galactosemia**       2/54
  IMD_235          Gal                13                   19.6            ***GALK1***      **c.1159G \> A**    **p.A387T**          **EP**                  **VUS**         **NA**     **Galactosemia**       2/54
  IMD_237          FT4                0.8                  0.2             ***DUOX2***      **c.2654G \> A**    **p.R885Q**          **KP**                  **LP**          **Het**    **CH**                 3/54
  IMD_238          FT4                0.8                  0.4             *TPO*            c.1061G \> T        p.W354L              EP                      VUS             NA         CH                     1/54
  IMD_264          17α-OHP/FT4        12.0/0.7             17.9/0.4        ***DUOXA2***     **c.738C \> G**     **p.Y246X**          **KP**                  **P**           **Het**    **CH**                 3/54

Reference sequences of *MUT*, *MCCC1*, *SLC25A13*, *DUOX2*, *TSHR*, *DUOXA2*, *PAX8*, *GALE*, *GALT*, *GALT*, *PAH*, *SLC5A5*, *GALK1*, and *TPO* were NM_000255, NM_001293273, NM_001160210, NM_014080, NM_000369, NM_207581, NM_003466, NM_001127621, NM_001258332, NM_000155, NM_000277, NM_000453, NM_000154, and NM_175722, respectively.

^\*^The metabolite units of C3, C5OH, Phe, Cit, Gal, TSH, FT4 and 17α-OHP were µmol/L, µmol/L, µmol/L, µmol/L, µmol/L, mU/L, ng/dL, ng/mL, respectively. Recurrent mutations are in **bold**.

Abbreviations: KP, known pathogenic mutation based on the Human Genome Mutation Database (DM) or ClinVar (pathogenic) databases; EP, expected pathogenic mutation based on population frequency, *in silico* prediction, and mutation type (loss of function mutations); P, pathogenic; LP, likely pathogenic; VUS, variant of unknown significance; NA, not applicable; Het, heterozygous; ComHet, compound heterozygous; Hom, homozygous; Cit, citrulline; GAL, galactose; TSH, thyroid stimulating hormone; FT4, free T4; MMA, Methylmalonic aciduria; 3-MCC deficiency, 3-methylcrotonyl-CoA carboxylase deficiency; PKU, Phenylketonuria; CTLN2, Type II citrullinemia; CH, Congenital hypothyroidism.

###### Unexpected detection of cases with biallelic mutations in genes irrelevant to metabolite abnormalities

![](alm-36-561-i003)

  Sample ID   Metabolites (Level; RR or cut-off)   Gene                                                                                                                                                                NT alteration   AA alteration   Conventional criteria   ACMG category   Status^\*^   Zygosity   Disease name   
  ----------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- --------------- ----------------------- --------------- ------------ ---------- -------------- ----------------
  IMD_35      C0 (4.06; cut-off 7)                 Cit (10.9; RR 2-55), Arg (16.8; RR 0--67) Gln (103; RR 0--300)                                                                                                      OTC             c.298+5G\>C     NA                      KP              LP           Known      Hom            OTC deficiency
  IMD_36      C0 (6.599, cut-off 7)                Glu (258; RR 0--805), C4 (0.23; RR 0--1.2), C6 (0.024; RR 0--0.5), C8 (0.007, RR 0--0.35), C10 (0.023 RR 0--0.5), C12 (0.033; RR 0--0.6), C18 (0.416; RR 0--2.13)   ETFB            c.155insT       p.P52fs                 EP              LP           Novel      Hom            GA Type II
  IMD_132     Gal (14.8; RR: less than 13)         Arg (1.162; RR 0--67.3), Orn (47.565; RR 0--175)                                                                                                                    SLC7A7          c.498T\>G       p.I166M                 EP              VUS          Novel      Hom            LPI
  IMD_162     C5 (1.909; RR: less than 0.81)       Arg (3.353; RR 0--67.31), Orn (34.551; RR 0--175)                                                                                                                   SLC7A7          c.498T\>G       p.I166M                 EP              VUS          Novel      Hom            LPI
  IMD_205     TSH (12.7; RR: less than 12)         Phe (29.4; RR 0--130), Tyr (34.268; RR 0--299), Phe/Tyr (0.858; RR 0--2.5)                                                                                          PAH             c.721C\>T       p.R241C                 KP              LP           Known      ComHet         PKU
  PAH         c.442-1G\>A                          NA                                                                                                                                                                  KP              P               Known                                                                          
  IMD_214     Gal (21.4; RR: less than 13)         TSH (3.2; RR; less than 12), FT4 (1.8; RR; less than 0.8)                                                                                                           DUOX2           c.3239T\>C      p.I1080T                KP              LP           Known      ComHet         CH
  DUOX2       c.2678A\>G                           p.N893S                                                                                                                                                             EP              VUS             Novel                                                                          
  IMD_216     Gal (13.5; RR: less than 13)         TSH (2.5; RR; less than 12), FT4 (2.3; RR; less than 0.8)                                                                                                           DUOX2           c.617G\>T       p.G206V                 KP              VUS          Known      ComHet         CH
              c.4232G\>A                           p.C1411Y                                                                                                                                                            KP              VUS             Known                                                                          
  IMD_234     Gal (27.7; RR: less than 13)         Cit (11.4; RR 2-55), Arg (14.7; RR 0--67), Gln (32; RR 0--300)                                                                                                      OTC             c.298+5G\>C     NA                      KP              LP           Known      Hom            OTC deficiency
  IMD_237     FT4 (0.2; RR less than 0.8)          C3 (0.4; RR 0.2-5)                                                                                                                                                  PCCB            c.1283C\>T      p.T428I                 KP              LP           Known      ComHet         PA
  PCCB        c.1316A\>G                           p.Y439C                                                                                                                                                             KP              LP              Known                                                                          
  IMD_243     FT4 (0.6; RR less than 0.8)          Arg (9.5; RR 0-67.3), Orn (36; RR 0-175)                                                                                                                            SLC7A7          c.498T\>G       p.I166M                 EP              VUS          Novel      Hom            LPI

Reference sequences of *OTC*, *ETFB*, *HAL*, *SLC7A7*, *PAH*, *DUOX2*, and *PCCB* were NM_000531.5, NM_001014763, NM_001258333, NM_001126105, NM_000277, NM_014080, and NM_000532, respectively. The metabolites units of TSH and FT4 were mU/L, ng/dL, ng/mL, respectively. The unit of the other metabolites was µmol/L.

^\*^The mutation status was assessed based on the Human Genome Mutation Database (DM) or ClinVar (pathogenic) databases.

Abbreviations: AA, amino acid; NT, nucleotide; KP, known pathogenic; EP, expected pathogenic based on population frequency, in silico prediction, and mutation type (loss of function mutations); P, pathogenic; LP, likely pathogenic; VUS, variant of unknown significance; RR, reference range; Gal, galactose; TSH, thyroid-stimulating hormone; FT4, free thyroxine; Cit, citrulline; Arg, arginine; Gln, glutamine; Glu, glutamate; Orn, ornithine; Phe, phenylalanine; Tyr, tyrosine; NA, not applicable; Het, heterozygous; ComHet, compound heterozygous; Hom, homozygous; OTC deficiency, Ornithine carbamoyltransferase deficiency; LPI, Lysinuric protein intolerance; CH, Congenital hypothyroidism; PA, Propionic academia, GA type II, Glutaric acidemia type II; PKU, Phenylketonuria.

###### Comparison of mutation-containing haplotypes between cases and controls

![](alm-36-561-i004)

  Genes        Haplotype ^\*^              SNPs in haplotype                                                                                                                                                                                                                                                                       Physical distance (bp)   \% in cases    \% in controls
  ------------ --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------- ----------------
  *DUOXA2*     TCCCGCCCCTATMAGTTTATCCTCC   rs397358, rs1473003, rs12913288, rs11635836, rs4775709, rs2467844, rs28662287, rs8024922, rs199138, rs269866, rs269862, rs269856, **p.Y138X**, rs16977681, rs175088, rs2271435, rs1648314, rs1648306, rs1648298, rs1706828, rs12439643, rs10519018, rs1706767, rs17533116, rs11636114   392,600                  66.7% (8/12)   0.00% (0/90)
  *DUOX2*      CCTTCTCCCTMATAGTTTATTCTCG   rs397358, rs1473003, rs12913288, rs11635836, rs4775709, rs2467844, rs28662287, rs8024922, rs199138, rs269866, **p.R885Q**, rs269862, rs269856, rs16977681, rs175088, rs2271435, rs1648314, rs1648306, rs1648298, rs1706828, rs12439643, rs10519018, rs1706767, rs17533116, rs11636114   392,600                  50.0% (3/6)    0.00% (0/90)
  *PCCB*       AATAATGTCGTMGATTC           rs16843560, rs4678435, rs3772390, rs9845457, rs561307, rs16843829, rs2290131, rs576771, rs1279840, rs9856769, rs518972, **p.Y439C**, rs696520, rs7620314, rs900048, rs4521165, rs7616204                                                                                                775,000                  100.0% (3/3)   0.00% (0/90)
  *SLC25A13*   TGGCAMCCCAC                 rs184381, rs10267710, rs6465486, rs3779486, rs2301629, **p.R285Pfs\*2**, rs12666465, rs6465496, rs35974282, rs4729249, rs12669236                                                                                                                                                       399,200                  100.0% (4/4)   0.00% (0/90)
  GALT         GCCMCCT                     rs10972175, rs11791806, rs10814130, **p.R224Q**, rs3808868, rs1104748, rs2812365                                                                                                                                                                                                        37,700                   100.0% (4/4)   0.00% (0/90)

The haplotype frequencies in mutation-positive cases were compared with those in 90 control individuals from the Korean HapMap.

^\*^M represents recurrent mutations (p.Y138X in *DUOXA2*, p.R885Q in *DUOX2*, p.Y439C in *PCCB*, p.R285Pfs^\*^2 in *SLC25A13*, p.R224Q in *GALT*).

Abbreviation: SNP, single nucleotide polymorphism.

[^1]: ^\*^Currently affiliated with the Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
